This pooled study comprehensively analyzed the incidence, time to onset, duration, and remission of RCCEP in patients with advanced or metastatic malignancies who received camrelizumab alone or in combination with other agents, as well as the associations between the occurrence of RCCEP and clinical outcomes including objective response and survival benefits. Data were derived from 10 clinical trials of camrelizumab in China (ClinicalTrials.gov Identifier: NCT02721589,40 (link)
 NCT02742935,42 (link)
 NCT03463876,36 (link)
 NCT03092895,30 (link),35 ,38 NCT03417895,33 (link)
 NCT03472365,39 (link)
 NCT02989922,13 (link)
 NCT03099382,15 (link)
 NCT03134872,19 (link)
 and NCT0370750918 (link)
). As of 30 June 2021, a total of 1305 patients received camrelizumab; among whom, 670 were treated with camrelizumab alone (Camre group), 296 with camrelizumab combined with the antiangiogenic agent apatinib (Camre-Apa group), and 339 with camrelizumab combined with cytotoxic chemotherapy [gemcitabine plus cisplatin (n = 134) or pemetrexed plus carboplatin (n = 205); Camre-Chemo group], respectively (Supplemental Table S1). In all 10 trials, tumor response was assessed according to the Response Evaluation Criteria in Solid Tumors (version 1.1), and all patients were followed up for survival. The reporting of this study refers to the STROBE statement (Supplemental Material 1).